NCT02617134Unknown1 期
Immunotherapy With Chimeric Antigen Receptor-Modified T Cells for MUC1 Positive Advanced Refractory Solid Tumor
PersonGen BioTherapeutics (Suzhou) Co., Ltd.1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2015年11月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Adverse events attributed to the administration of the anti-MUC1 CAR-T cells
研究概览
简要总结
The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in patients with MUC1 positive relapsed or refractory solid tumor.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female subjects with MUC1+ malignancies in patients with no available curative treatment options who have limited prognosis (several months to < 2 year survival) with currently available therapies will be enrolled:
- •Eligible diseases: MUC1+ malignant glioma of brain, colorectal carcinoma and gastric carcinoma.
- •1a. Malignant Glioma of Brain Failure after previous standard of care initial treatment of glioblastoma multiforme; documentation by magnetic resonance imaging (MRI) of an interval increase in nodular gadolinium enhancement consistent with recurrent malignant glioma suitable for therapeutic re-resection; previous pathological diagnosis of World Health Organization (WHO) Grade IV glioma;
- •1b. Colorectal Carcinoma Patients must have histologically proven adenocarcinoma primary to the colon or rectum and clinical or pathologic evidence of distant metastasis;
- •1c. Gastric Carcinoma Histologically confirmed adenocarcinoma of the stomach, gastroesophageal junction or esophagus; metastatic disease or locally advanced disease not amenable to curative surgery.
- •Patients 18 years of age or older, and must have a life expectancy > 12 weeks.
- •MUC1 is expressed in malignancy tissues by immuno-histochemical (IHC).
- •Eastern cooperative oncology group (ECOG) performance status of 0-2 or karnofsky performance status (KPS) score is higher than
- •Adequate venous access for apheresis or venous sampling, and no other contraindications for leukapheresis.
- •Females of child-bearing potential must have a negative pregnancy test and all subjects must agree to use an effective method of contraception for up to two weeks after the last infusion of CAR T cells.
- •Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements: White blood cell count (WBC) ≥ 2500c/ml, Platelets ≥ 50×10^9/L, Hb ≥ 9.0g/dL, lymphocyte (LY) ≥ 0.7×10^9/L, LY% ≥ 15%, Alb ≥ 2.8g/dL, serum lipase and amylase < 1.5×upper limit of normal, serum creatinine ≤ 2.5mg/dL, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5×upper limit of normal, serum total bilirubin ≤ 2.0mg/dL. These tests must be conducted within 7 days prior to registration.
- •Ability to give informed consent.
排除标准
- •The transduction efficiency of the T cells is less than 30% or the amplification of the T cells via artificial antigen presenting cell (aAPC) stimulation is less than 5 times.
- •Pregnant or nursing women may not participate.
- •Known HIV, hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
- •Serious illness or medical condition which would not permit the patient to be managed according to the protocol, including active uncontrolled infection, major cardiovascular, coagulation disorders, respiratory or immune system, myocardial infarction, cardiac arrhythmias, obstructive/restrictive pulmonary disease, or psychiatric or emotional disorders.
- •History of severe immediate hypersensitivity to any of the agents including cyclophosphamide, fludarabine, or aldesleukin.
- •Concurrent use of systemic steroids. Recent or current use of inhaled steroids is not exclusionary.
- •Previously treatment with any gene therapy products.
- •The existence of unstable or active ulcers or gastrointestinal bleeding.
- •Patients with portal vein vascular invasion or extrahepatic, are excluded from this study.
- •Patients with a history of organ transplantation or are waiting for organ transplantation.
- •Patients need anticoagulant therapy (such as warfarin or heparin).
- •Patients need long-term antiplatelet therapy (aspirin at a dose > 300mg/d; clopidogrel at a dose > 75mg/d).
- •Patients treated by radiotherapy within 4 weeks prior the first apheresis.
- •Patients using fludarabine or cladribine chemotherapy within two years.
结局指标
主要结局
Adverse events attributed to the administration of the anti-MUC1 CAR-T cells
时间窗: 2 years
Determine the toxicity profile of the MUC1 targeted CAR-T cells with Common Toxicity Criteria for Adverse Effects (CTCAE) version 4.0.
次要结局
- Objective Response Rate(Safety follow-up is 100 days from last CAR-T infusion.)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
ALaCART-B: Acute Leukemia and Chimeric Antigen Receptor-T Cell Therapy for B-lymphoblastic Leukemia.Lymphoblastic Leukemia, Acute, ChildhoodLymphoblastic LeukemiaLymphoblastic Leukemia, Acute AdultLymphoblastic Leukemia in ChildrenCARCAR T-Cell-Related Encephalopathy SyndromeNCT05038696National University Hospital, Singapore40
撤回
1 期
CAR-T Cell Immunotherapy for HCC Targeting GPC3GPC3 Positive Hepatocellular CarcinomaCAR-T Cell ImmunotherapyNCT02723942Fuda Cancer Hospital, Guangzhou
撤回
1 期
CAR-T Cell Immunotherapy for EphA2 Positive Malignant Glioma PatientsEphA2 Positive Malignant GliomaCAR-T Cell ImmunotherapyNCT02575261Fuda Cancer Hospital, Guangzhou
撤回
1 期
CAR-T Cell Immunotherapy for GD2 Positive Glioma PatientsGlioma of BrainCAR-T Cell ImmunotherapyNCT04406610Fuda Cancer Hospital, Guangzhou
撤回
1 期
CAR-T Cell Immunotherapy for GD2 Positive Glioma PatientsGD2 Positive GliomaCAR-T Cell ImmunotherapyNCT03252171Fuda Cancer Hospital, Guangzhou